CXCR4-Targeted Necrosis-Inducing Peptidomimetic for Treating Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Triple-negative breast cancer (TNBC) is aggressive with poor outcomes.
• CXCR4 receptor is a key target in breast cancer.
• Novel therapeutic strategies are needed for TNBC.

Purpose of the Study:

• To develop and evaluate a CXCR4-targeted peptidomimetic, CTCE-KLAK, for TNBC treatment.
• To assess the in vitro and in vivo antitumor activity of CTCE-KLAK.
• To elucidate the mechanism of cell death induced by CTCE-KLAK.

Main Methods:

• Development of CTCE-KLAK, a fusion of CTCE-9908 and KLAKLAK peptides.
• In vitro cytotoxicity assays on breast cancer and normal cells.
• In vivo studies using the 4T1 mouse metastatic breast cancer model.
• Analysis of cell death pathways (caspase cleavage, pan-caspase inhibition).

Main Results:

• CTCE-KLAK demonstrated selective necrosis in TNBC cells, sparing normal cells.
• No caspase activation was observed, indicating non-apoptotic cell death.
• CTCE-KLAK significantly inhibited tumor growth and lung metastasis in vivo.
• Tumor selectivity was linked to receptor-mediated internalization.

Conclusions:

• CTCE-KLAK is a potent, cell-selective inducer of necrosis.
• The peptidomimetic shows significant preclinical efficacy against TNBC.
• CTCE-KLAK represents a promising CXCR4-targeted therapeutic candidate for TNBC.